Hyper immunoglobulin M syndrome due to CD40 deficiency: Clinical, molecular, and immunological features

Immunological Reviews

Volumn 203, Issue , 2005, Pages 48-66

  Lougaris, Vassilios ^a   Badolato, Raffaele ^a   Ferrari, Simona ^b   Plebani, Alessandro ^a,c  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c Clinica Pediatrica   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; IMMUNOGLOBULIN A; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; TUMOR NECROSIS FACTOR RECEPTOR;

B LYMPHOCYTE; CLINICAL FEATURE; DENDRITIC CELL; GENE MUTATION; GERMINAL CENTER; HUMAN; HUMORAL IMMUNE DEFICIENCY; HYPERIMMUNOGLOBULINEMIA M; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN GENE; LIGAND BINDING; LYMPHOCYTE PROLIFERATION; MACROPHAGE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION;

ANTIGENS, CD40; B-LYMPHOCYTES; DENDRITIC CELLS; HUMANS; HYPERGAMMAGLOBULINEMIA; IMMUNOGLOBULIN M; IMMUNOLOGIC DEFICIENCY SYNDROMES; MUTATION;

EID: 13144253109     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0105-2896.2005.00229.x     Document Type: Review

References (156)

1. Notarangelo LD, Duse M, Ugazio AG. Immunodeficiency with hyper-IgM (HIM). Immunodefic Rev 1992;3:101-121.
2. Burtin P. Un exemple d'agammaglobulinémie atypique (un cas de grande hypogammaglobulinémie avec augmentation de la beta2- macroglobuline). Rev Fr Etud Clin Biol 1961;6:286-289.
3. Hong R, Schubert WK, Perrin EV, West CD. Antibody deficiency syndrome associated with beta-2 macroglobulinemia. J Pediatr 1962;61:831-842.
4. Rosen FS, Janeway CA. The gamma globulins. III. The antibody deficiency syndromes. N Engl J Med 1966;275:709-715.
5. Mayer L, et al. Evidence for a defect in 'switch' T cells in patients with immunodeficiency and hyperimmunoglobulinemia M. N Engl J Med 1986;314:409-413.
6. Revy P, et al. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the hyper-IgM syndrome (HIGM2). Cell 2000;102:565-575.
7. Ferrari S, et al. Mutations of CD40 gene cause an autosomal recessive form of immunodeficiency with hyper IgM. Proc Natl Acad Sci USA 2001;98:12614-12619.
8. Jain A, Ma CA, Liu S, Brown M, Cohen J, Strober W. Specific missense mutations in NEMO result in hyper-IgM syndrome with hypohydrotic ectodermal dysplasia. Nat Immunol 2001;2:223-228.
9. Doffinger R, et al. X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling. Nat Genet 2001;27:277-285.
10. Imai K, et al. Human uracil-DNA glycosylase deficiency associated with profoundly impaired immunoglobulin class-switch recombination. Nat Immunol 2003;4:1023-1028.
11. Levy J, et al. Clinical spectrum of X-linked hyper-IgM syndrome. J Pediatr 1997;131:47-54.
12. Koho H, et al. Monoclonal antibodies to antigens associated with transitional cell carcinoma of the human urinary bladder. I. Determination of the selectivity of six antibodies by cell-ELISA and immunofluorescence. Cancer Immunol Immunother 1984;17:165-172.
13. van Kooten C, Banchereau J. Functional role of CD40 and its ligand. Int Arch Allergy Immunol 1997;113:393-399.
14. Tan J, et al. CD40 is expressed and functional on neuronal cells. EMBO J 2002;21:643-652.
15. Hakkarainene T, et al. CD40 is expressed on ovarian cancer cells and can be utilized for targeting adenoviruses. Clin Cancer Res 2003;9:619-624.
16. Gordon J, Millsum MJ, Guy GR, Ledbetter JA. Resting B lymphocytes can be triggered directly through the CDw40 (Bp50) antigen, a comparison with IL-4 mediated signaling. J Immunol 1988;140:1425-1430.
17. Valle A, Zuber CE, Defrance T, Djossou O, Derie M, Banchereau J. Activation of human B lymphocytes through CD40 and interleukin 4. Eur J Immunol 1989;19:1463-1467.
18. Bjorck P, Axelsson B, Paulie S. Expression of CD40 and CD43 during activation of human B lymphocytes. Scand J Immunol 1991;33:211-218.
19. Bjorck P, Elenstrom-Magnusson C, Rosen A, Severinson E, Paulie S. CD23 and CD21 function as adhesion molecules in homotypic aggregation of human B lymphocytes. Eur J Immunol 1993;23:1771-1775.
20. Barrett TB, Shu G, Clark EA. CD40 signaling activates CD11a/CD18 (LFA-1)-mediated adhesion in B cells. J Immunol 1991;146:1722-1729.
21. Stamenkovic I, Clark EA, Seed B. A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. EMBO J 1989;8:1403-1410.
22. Noelle RJ, Roy M, Shepherd DM, Stamenkovic I, Ledbetter JA, Aruffo A. A 39 kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc Natl Acad Sci USA 1992;89:6550-6554.
23. Zubler RH, Werner-Favre C, Wen L, Sekita. K-I, Straub C. Theoretical and practical aspects of B activation: murine and human systems. Immunol Rev 1987;99:231-299.
24. Hirohata S, Jelinek D, Lipsky PE. T-cell dependent activation of B cell proliferation and differentiation by immobilized monoclonal antibodies to CD3. J Immunol 1988;140:3736-3744.
25. Armitage RJ, et al. Molecular and biological characterization of a murine ligand for CD40. Nature 1992;357:80-82.
26. Lederman S, Yellin MJ, Inghirami G, Lee JJ, Knowles DM, Chess L. Molecular interactions mediating T-B lymphocyte collaboration in human lymphoid follicles. Roles of T cell-B-cell-activating molecule (5c8 antigen) and CD40 in contact-dependent help. J Immunol 1992;149:3817-3826.
27. Yellin MJ, Lee JJ, Chess L, Ledermann S. A human CD4-leukemic subclone with contact dependent helper function. J Immunol 1991;147:3389-3395.
28. Graf D, Korthauer U, Mages HW, Senger G, Kroczek RA. Cloning of TRAP, a ligand for CD40 on human T cells. Eur J Immunol 1992;22:3191-3194.
29. Hollenbaugh D, et al. The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity. EMBO J 1992;11:4313-4321.
30. Lederman S, Yellin MJ, Krichevsky A, Belko J, Lee JJ, Chess L. Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (help). J Exp Med 1992;175:1091-1101.
31. Gauchat JF, et al. Human CD40-ligand: molecular cloning, cellular distribution and regulation of expression by factors controlling IgE production. FEBS Lett 1993;315:259-266.
32. Blossom S, Chu EB, Weigle WO, Gilbert KM. CD40 ligand expressed on B cells in the BXSB mouse model of ayatemic lupus erythematosous. J Immunol 1997;159:4580-4586.
33. Grammer AC, Bergman MC, Miura Y, Fujita K, Davis LS, Lipsky PE. The CD40 ligand expressed by human B cells costimulates B cell responses. J Immunol 1995;154:4996-5010.
34. Grammer AC, McFarland RD, Henney J, Darnell BF, Lipsky PE. Expression, regulation and function of B-cell expressed CD154 in germinal centers. J Immunol 1999;163:4150-4159.
35. Devi BS, van Noordin S, Krausz T, Davies KA. Peripheral blood lymphocytes in SLE-Hyperexpression of CD154 on T and B lymphocytes and increased number of double negative T cells. J Autoimmun 1998;11:471-475.
36. Gauchat J-F, et al. CD40 ligand is functionally expressed on human eosinophils. Eur J Immunol 1995;25:863-865.
37. Pinchuk LM, Klaus SJ, Magaletti DM, Pinchuk GV, Noprsen JP, Clark EA. Functional CD40 ligand expressed by human blood dendritic cells is upregulated by CD40 ligation. J Immunol 1996;157:4363-4370.
38. Mach F, et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA 1994;94:1931-1936.
39. Aruffo A, et al. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell 1993;72:291-300.
40. Korthauer U, et al. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature 1993;36I:539-541.
41. Di Santo JP, Bonnefoy JY, Gauchat JF, Fischer A, de Saint Basile G. CD40 ligand mutations in X-linked immunodeficiency with hyper-IgM. Nature 1993;361:539-541.
42. Allen RC, et al. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science 1993;259:990-993.
43. Fuleihan R, et al. Defective expression of the CD40 ligand in X chromosome-linked immunoglobulin deficiency with normal or elevated IgM. Proc Natl Acad Sci USA 1993;90:2170-2173.
44. Renshaw BR, et al. Humoral immune responses in CD40-ligand deficient mice. J Exp Med 1994;180:1889-1890.
45. Xu J, et al. Mice deficient for CD40 ligand. Immunity 1994;1:423-431.
46. Castigli E, et al. CD40-deficient mice generated by recombination- activating gene-2-deficient blastocyst complementation. Proc Natl Acad Sci USA 1994;91:12135-12139.
47. Kawabe T, et al. The immune response in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity 1994;1:167-178.
48. Brines RD, Klaus GGB. Polyclonal activation of immature B cells by preactivated T cells: the role of Il-4 and CD40 ligand. Int Immunol 1993;5:1445-1450.
49. Wheller K, Pound JD, Gordon J, Jefferis R. Engagement of CD40 lowers the threshold for activation of resting B cells via antigen receptor. Eur J Immunol 1993;23:1165-1168.
50. low T cells. Eur J Immunol 1994;24:2993-2999.
51. Bishop GA, Warren WD, Berton MT. Signaling via MHC class II molecules and antigen receptors enhances the B cell response to gp39/CD40 ligand. Eur J Immunol 1995;25:1230-1238.
52. Hu HM, Lee SC, Marin E, Ryan DH, Insel RA. Telomerase is up-regulated in human germinal center B cells in vivo and can be re-expressed in memory B cells activated in vitro. J Immunol 1997;159:1068-1071.
53. Ishida T, Kobayashi N, Tojo T, Ishida S, Yamamoto T, Inoue J. CD40 signaling-mediated induction of Bcl-XL, Cdk4, and Cdk6. Implication of their cooperation in selective B cell growth. J Immunol 1995;155:5527-5535.
54. Randall TD, Heath AW, Santos-Argumedo L, Howard MC, Weissman IL, Lund FE. Arrest of B lymphocyte terminal differentiation by CD40 signaling: mechanism for lack of antibody secreting cells in germinal centers. Immunity 1998;8:733-742.
55. Arpin C, et al. Generation of memory B cells and plasma cells in vitro. Science 1995;268:720-722.
56. Facchetti F, Appiani C, Salvi L, Levy J, Notarangelo LD. Immunohistologic analysis of ineffective CD40-CD40 ligand interaction in lymhoid tissues from patients with X-linked immunodeficiency with hyper-IgM. J Immunol 1995;154:6624-6633.
57. Oxenius A, et al. CD40-CD40 ligand interactions are critical in T-B cooperation but not for other anti-viral CD4+ T cell functions. J Exp Med 1996;183:2209-2218.
58. Stavnezer J. Molecular processes that regulate class switching. Curr Top Microbiol Immunol 2000;245:127-168.
59. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 2000;102:553-563.
60. Minegishi Y, et al. Mutations in activation-induced cytidine deaminase in patients with hyper IgM syndrome. Clin Immunol 2000;97:203-210.
61. Zhu Y, Nonoyama S, Morio T, Muramatsu M, Honjo T, Mizutani S. Type two hyper-IgM syndrome caused by mutation in activation-induced cytidine deaminase. J Med Dent Sci 2003;50:41-46.
62. Brezinschek HP, Dorner T, Monson NL, Brezinschek RI, Lipsky PE. The influence of CD40-CD154 interactions on the expressed human V (H) repertoire: analysis of V (H) genes expressed by individual B cells of a patient with X-linked hyper-IgM syndrome. Int Immunol 2000;12:767-775.
63. Monson NL, Foster SJ, Brezinschek HP, Brezinschek RI, Dorner T, Lipsky PE. The role of CD40-CD40 ligand (CD154) interactions in immunoglobulin light chain repertoire generation and somatic mutation. Clin Immunol 2001;100:71-81.
64. Stout RD, Suttles J. The many roles of CD40 in cell-mediated inflammatory responses. Immunol Today 1996;17:487-492.
65. Grewal IS, Flavell RA. The role of CD40 ligand in costimulation and T-cell activation. Immunol Rev 1996;153:85-106.
66. Stout RD, Suttles J, Xu J, Grewal IS, Flavell RA. Impaired T cell-mediated macrophage activation in CD40 ligand-deficient mice. J Immunol 1996;156:8-11.
67. Kiener PA, Moran-Davis P, Rankin BM, Wahl AF, Aruffo A, Hollenbaugh D. Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes. J Immunol 1995;155:4917-4925.
68. Caux C, et al. Activation of human dendritic cells through CD40 cross-linking. J Exp Med 1994;180:1263-1272.
69. Banchereau J, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767-811.
70. Hu HM, O'Rourke K, Boguski MS, Dixit VM. A novel RING finger protein interacts with the cytoplasmic domain of CD40. J Biol Chem 1994;269:30069-30072.
71. Rothe M, Wong SC, Henzel WJ, Goeddel DV. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell 1994;78:681-692.
72. Regnier CH, et al. Presence of a new conserved domain in CART1, a novel member of the tumor necrosis factor receptor-associated protein family, which is expressed in breast carcinoma. J Biol Chem 1995;270:25715-25721.
73. Ishida TK, et al. TRAF5, a novel tumor necrosis factor receptor-associated factor family protein, mediates CD40 signaling. Proc Natl Acad Sci USA 1996;93:9437-9442.
74. Ishida T, et al. Identification of TRAF6, a novel tumor necrosis factor receptor-associated factor protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region. J Biol Chem 1996;271:28745-28748.
75. Xu LG, Li LY, Shu HB. TRAF7 potentiates MEKK3-induced AP1 and CHOP activation and induces apoptosis. J Biol Chem 2004;279:17278-17282.
76. Wajant H, Grell M, Scheurich P. TNF receptor associated factors in cytokine signaling. Cytokine Growth Factor Rev 1999;10:15-26.
77. Hostager BS, Catlett IM, Bishop GA. Recruitment of CD40 and tumor necrosis factor receptor-associated factors 2 and 3 to membrane microdomains during CD40 signaling. J Biol Chem 2000;275:15392-15398.
78. Bishop GA, Hostager BS. Signaling by CD40 and its mimics in B cell activation. Immunol Res 2001;24:97-109.
79. Pullen SS, Miller HG, Everdeen DS, Dang TT, Crute JJ, Kehry MR. CD40-tumor necrosis factor receptor-associated factor (TRAF) interactions, regulation of CD40 signaling through multiple TRAF binding sites and TRAF hetero-oligomerization. Biochemistry 1998;37:11836-11845.
80. Franken M, Devergne O, Rosenzweig M, Annis B, Kieff E, Wang F. Comparative analysis identifies conserved tumor necrosis factor receptor-associated factor 3 binding sites in the human and simian Epstein-Barr virus oncogene LMP1. J Virol 1996;70:7819-7826.
81. Lu LF, Cook WJ, Lin LL, Noelle RJ. CD40 signaling through a newly identified tumor necrosis factor receptor-associated factor 2 (TRAF2) binding site. J Biol Chem 2003;278:45414-45418.
82. Werneburg BG, Zoog SJ, Dang TT, Kehry MR, Crute JJ. Molecular characterization of CD40 signaling intermediates. J Biol Chem 2001;276:43334-43342.
83. Zarnegar B, He JQ, Oganesyan G, Hoffmann A, Baltimore D, Cheng G. Unique CD40-mediated biological program in B cell activation requires both type 1 and type 2 NF-kappaB activation pathways. Proc Natl Acad Sci USA 2004;101:8108-8113.
84. Choi MS, Brines RD, Holman MJ, Klaus GG. Induction of NF-AT in normal B lymphocytes by anti-immunoglobulin or CD40 ligand in conjunction with IL-4. Immunity 1994;1:179-187.
85. Francis DA, Karras JG, Ke XY, Sen R, Rothstein TL. Induction of the transcription factors NF-kappa B, AP-1 and NF-AT during B cell stimulation through the CD40 receptor. Int Immunol 1995;7:151-161.
86. Eliopoulos AG, Wang CC, Dumitru CD, Tsichlis PN. Tpl2 transduces CD40 and TNF signals that activate ERK and regulates IgE induction by CD40. EMBO J 2003;22:3855-3864.
87. Karras JG, Wang Z, Huo L, Frank DA, Rothstein TL. Induction of STAT protein signaling through the CD40 receptor in B lymphocytes: distinct STAT activation following surface Ig and CD40 receptor engagement. J Immunol 1997;159:4350-4355.
88. Hanissian SH, Geha RS. Jak3 is associated with CD40 and is critical for CD40 induction of gene expression in B cells. Immunity 1997;6:379-387.
89. Karras JG, Wang Z, Huo L, Howard RG, Frank DA, Rothstein TL. Signal transducer and activator of transcription-3 (STAT3) is constitutively activated in normal, self-renewing B-1 cells but only inducibly expressed in conventional B lymphocytes. J Exp Med 1997;185:1035-1042.
90. Lam N, Sugden B. CD40 and its viral mimic, LMP1: similar means to different ends. Cell Signal 2003;15:9-16.
91. Gulbins E, et al. Activation of the Ras signaling pathway by the CD40 receptor. J Immunol 1996;157:2844-2850.
92. Padmore L, An S, Gunby RH, Kelly K, Radda GK, Knox KA. CD40-triggered protein tyrosine phosphorylation on Vav and on phosphatidylinositol 3-kinase correlates with survival of the Ramos-Burkitt lymphoma B cell line. Cell Immunol 1997;177:119-128.
93. Aagaard-Tillery KM, Jelinek DF. Phosphatidylinositol 3-kinase activation in normal human B lymphocytes. J Immunol 1996;156:4543-4554.
94. Faris M, Gaskin F, Parsons JT, Fu SM. CD40 signaling pathway: anti-CD40 monoclonal antibody induces rapid dephosphorylation and phosphorylation of tyrosine-phosphorylated proteins including protein tyrosine kinase Lyn, Fyn, and Syk and the appearance of a 28-kD tyrosine phosphorylated protein. J Exp Med 1994;179:1923-1931.
95. Merluzzi S, et al. CD40 stimulation induces Pax5/BSAP and EBF activation through a APE/Ref-1-dependent redox mechanism. J Biol Chem 2004;279:1777-17786.
96. Tone M, Tone Y, Fairchild PJ, Wykes M, Waldmann H. Regulation of CD40 function by its isoforms generated through alternative splicing. Proc Natl Acad Sci USA 2001;98:1751-1756.
97. Weller S, et al. Human blood IgM 'memory' B cells are circulating splenic marginal zone B cells harboring a pre-diversified immunoglobulin repertoire. Blood 2004;104:3647-3654
98. Brodeur SR, et al. C4b-binding protein (C4BP) activates B cells through the CD40 receptor. Immunity 2003;18:837-848.
99. Clark EA, Craxton A. CD40 bridge between innate and adaptive immunity. Immunity 2003;18:724-725.
100. Grammer AC, Bergman MC, Miura Y, Fujita K, Davis LS, Lipsky PE. The CD40 ligand expressed by human B cells costimulates B cell responses. J Immunol 1995;154:4996-5010.
101. Grammer AC, McFarland RD, Heaney J, Darnell BF, Lipsky PE. Expression, regulation, and function of B cell-expressed CD154 in germinal centers. J Immunol 1999;163:4150-4159.
102. Morio T, Hanissian S, Geha RS. Characterization of a 23-kDa protein associated with CD40. Proc Natl Acad Sci USA 1995;92:11633-11636.
103. Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001;106:255-258.
104. Caux C, et al. Activation of human dendritic cells through CD40 cross-linking. J Exp Med 1994;180:1263-1272.
105. Fontana S, et al. Functional defects of dendritic cells in patients with CD40 deficiency. Blood 2003;102:4099-4106.
106. Gao JX, et al. CD40-deficient dendritic cells producing interleukin-10, but not interleukin-12, induce T-cell hyporesponsiveness in vitro and prevent acute allograft rejection. Immunology 1999;98:159-170.
107. Gray D, Dullforce P, Jainandunsing S. Memory B cell development but not germinal center formation is impaired by in vivo blockade of CD40-CD40 ligand interaction. J Exp Med 1994;180:141-155.
108. Lane P, Brocker T, Hubele S, Padovan E, Lanzavecchia A, McConnell F. Soluble CD40 ligand can replace the normal T cell-derived CD40 ligand signal to B cells in T cell-dependent activation. J Exp Med 1993;177:1209-1213.
109. Grewal IS, Xu J, Flavell RA. Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. Nature 1995;378:617-620.
110. Corinti S, Albanesi C, la Sala A, Pastore S, Girolomoni G. Regulatory activity of autocrine IL-10 on dendritic cell functions. J Immunol 2001;166:4312-4318.
111. Banchereau J, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767-811.
112. Vremec D, et al. The surface phenotype of dendritic cells purified from mouse thymus and spleen: investigation of the CD8 expression by a subpopulation of dendritic cells. J Exp Med 1992;176:47-58.
113. Olweus J, et al. Dendritic cell ontogeny: a human dendritic cell lineage of myeloid origin. Proc Natl Acad Sci USA 1997;94:12551-12556.
114. Grouard G, Clark EA. Role of dendritic and follicular dendritic cells in HIV infection and pathogenesis. Curr Opin Immunol 1997;9:563-567.
115. Rissoan MC, et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999;283:1183-1186.
116. Penna G, Sozzani S, Adorini L. Cutting edge: selective usage of chemokine receptors by plasmacytoid dendritic cells. J Immunol 2001;167:1862-1866.
117. Siegal FP, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999;284:1835-1837.
118. Chehimi J, et al. Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals. J Immunol 2002;168:4796-4801.
119. Cella M, Facchetti F, Lanzavecchia A, Colonna M. Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent TH1 polarization. Nat Immunol 2000;1:305-310.
120. Kutukculer N, et al. Disseminated Cryptosporidium infection in an infant with hyper-IgM syndrome caused by CD40 deficiency. J Pediatr 2003;142:194-196.
121. Winkelstein JA, et al. The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients. Medicine (Baltimore) 2003;82:373-384.
122. Garside P, Ingulli E, Merica RR, Johnson JG, Noelle RJ, Jenkins MK. Visualization of specific B and T lymphocyte interactions in the lymph node. Science 1998;281:96-99.
123. Caux C, et al. Activation of human dendritic cells through CD40 crosslinking. J Exp Med 1994;180:1263-1272.
124. Kiener PA, Moran-Davis P, Rankin BM, Wahl AF, Aruffo A, Hollenbaugh D. Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes. J Immunol 1995;155:4917-4925.
125. Grewal IS, Xu J, Flavell RA. Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. Nature 1995;378:617-620.
126. Soong L, et al. Disruption of CD40-CD40 ligand interactions results in an enhanced susceptibility to Leishmania amazonensis infection. Immunity 1996;4:263-273.
127. Campbell KA, Ovendale PJ, Kennedy MK, Fanslow WC, Reed SG, Maliszewski CR. CD40 ligad is required for protective cell-mediated immunity to Leishmania major. Immunity 1996;4:283-289.
128. Seguin R, Kasper LH. Sensitized lymphocytes and CD40 ligation augment interleukin-12 production by human dendritic cells in response to Toxoplasma gondii. J Infect Dis 1999;179:467-474.
129. Subauste CS, Wessendarp M. Human dendritic cells discriminate between viable and killed Toxoplasma gondii tachyzoites: dendritic cell activation after infection with viable parasites results in CD28 and CD40 ligand signaling that controls IL-12-dependent and -independent T cell production of IFN-gamma. J Immunol 2000;165:1498-1505.
130. Subauste CS. CD154 and type-1 cytokine response: from hyper IgM syndrome to human immunodeficiency virus infection. J Infect Dis 2002;185:583-589.
131. Retini C, Casadevall A, Pietrella D, Monari C, Palazzetti B, Vecchiarelli A. Specific activated T cells regulate IL-12 production by human monocytes stimulated with Cryptococcus neoformans. J Immunol 1999;162:1618-1623.
132. Cosyns M, Tsirkin S, Jones M, Flavell R, Kikutani H, Hayward AR. Requirement of CD40-CD40 ligand interaction for elimination of Cryptosporidium parvum from mice. Infect Immun 1998;66:603-607.
133. Hayashi T, Rao SP, Meylan PR, Kornbluth RS, Catanzaro A. Role of CD40 ligand in Mycobacterium avium infection. Infect Immun 1999;67:3558-3565.
134. Marriot I, Hammond TG, Thomas EK, Bost KL. Salmonella efficiently enter and survive within cultured CD11c+ dendritic cells initiating cytokine expression. Eur J Immunol 1999;29:1107-1115.
135. Wiley JA, Harmsen AG. CD40 ligand is required for resolution of Pneumocystis carinii pneumonia in mice. J Immunol 1995;155:3525-3529.
136. Netea MG, Meer JW, Verschueren I, Kullberg BJ. CD40/CD40 ligand interactions in the host defense against disseminated Candida albicans infection: the role of macrophage-derived nitric oxide. Eur J Immunol 2002;32:1455-1463.
137. Quartier P, et al. Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to activation-induced cytidine deaminase deficiency. Clin Immunol 2004;110:22-29.
138. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 2000;102:553-563.
139. Di Noia J, Neuberger MS. Altering the pathway of immunoglobulin hypermutation by inhibiting uracil-DNA glycosylase. Nature 2002;419:43-48.
140. Benkerrou M, Gougeon ML, Griscelli C, Fischer A. Hypogammaglobulinemia G and A with hypergammaglobulinemia M. Apropos of 12 cases. Arch Fr Pediatr 1990;47:345-349.
141. McLauchlin J, Amar CF, Pedraza-Diaz S, Mieli-Vergani G, Hadzic N, Davies EG. Polymerase chain reaction-based diagnosis of infection with Cryptosporidium in children with primary immunodeficiencies. Pediatr Infect Dis J 2003;22:329-335.
142. Tomizawa D, et al. Allogeneic hematopoietic stem cell transplantation for seven children with X-linked hyper-IgM syndrome: a single center experience. Am J Hematol 2004;76:33-39.
143. Gennery AR, et al. Treatment of CD40 ligand deficiency by hematopoietic stem cell transplantation: a survey of the European experience, 1993-2002. Blood 2004;103:1152-1157.
144. Davies EG, et al. Cholangiopathy in children with combined immunodeficiencies. Mol Immunol 1998;35:731.
145. Hayward AR, et al. Cholangiopathy and tumors of the pancreas, liver, and biliary tree in boys with X-linked immunodeficiency with hyper-IgM. J Immunol 1997;158:977-983.
146. Kutukculer N, Aksoylar S, Kansoy S, Cetingul N, Notarangelo LD. Outcome of hematopoietic stem cell transplantation in hyper-IgM syndrome caused by CD40 deficiency. J Pediatr 2003;143:141-142.
147. Ayala J, Olofsson B, Tavitian A, Prochiantz A. Developmental and regional regulation of rab3: a new brain specific 'ras-like' gene. J Neurosci Res 1989;22:241-246.
148. Ayala J, Olofsson B, Touchot N, Zahraoui A, Tavitian A, Prochiantz A. Developmental and regional expression of three new members of the ras-gene family in the mouse brain. J Neurosci Res 1989;22:384-389.
149. Zirrgiebel U, Lindholm D. Constitutive phosphorylation of TrkC receptors in cultured cerebellar granule neurons might be responsible for the inability of NT-3 to increase neuronal survival and to activate p21 Ras. Neurochem Res 1996;21:851-859.
150. Encinas M, Iglesias M, Llecha N, Comella JX. Extracellular-regulated kinases and phosphatidylinositol 3-kinase are involved in brain-derived neurotrophic factor-mediated survival and neuritogenesis of the neuroblastoma cell line SH-SY5Y. J Neurochem 1999;73:1409-1421.
151. Mach F, Schonbeck U, Bonnefoy JY, Pober JS, Libby P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation 1997;96:396-399.
152. Morris AE, Remmele RL, Klinke R, Macduff BM, Fanslow WC, Armitage RJ. Incorporation of an isoleucine zipper motif enhances the biological activity of soluble CD40L (CD154). J Biol Chem 1999;274:418-423.
153. Weller S, et al. CD40-CD40L independent Ig gene hypermutation suggests a second B cell diversification pathway in humans. Proc Natl Acad Sci USA 2001;98:1166-11670.
154. Kruetzmann S, et al. Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. J Exp Med 2003;197:939-945.
155. Agematsu K, et al. B cell subpopulations separated by CD27 and crucial collaboration of CD27+ B cells and helper T cells in immunoglobulin production. Eur J Immunol 1997;27:2073-2079.
156. Maurer D, et al. IgM and IgG but not cytokine secretion is restricted to the CD27+ B lymphocyte subset. J Immunol 1992;148:3700-3705.